S. Grupp
Oncology · 2009–2020
A researcher in the Science corpus: 17 papers; trusts 3 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 143 citations into it; #480 of 1,698 by trust here, #99 by citations
- Genetics — 64 citations into it; #3,511 of 6,854 by trust here, #290 by citations
Whom S. Grupp trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Grupp overall
Papers from S. Grupp's perspective
Ordered by how strongly the researchers S. Grupp trusts endorse each paper. Same corpus, a different order for every researcher.
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (Science Translational Medicine)
- Familial and acquired hemophagocytic lymphohistiocytosis (European Journal of Pediatrics)
- A Simple Sequentially Rejective Multiple Test Procedure
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 (International Journal on Biological Sciences)
- Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis (Pediatric Blood & Cancer)
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (Clinical Cancer Research)
- C-reactive protein: a critical update. (Journal of Clinical Investigation)
Their papers
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo (2009) — 1,165 citations
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. (2020) — 1,159 citations
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges (2020) — 1,034 citations
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells (2018) — 3,090 citations
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) — 595 citations
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia (2018) — 4,690 citations
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia (2016) — 965 citations
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy (2015) — 1,165 citations
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. (2015) — 663 citations
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015) — 1,615 citations
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies (2014) — 704 citations
- Current concepts in the diagnosis and management of cytokine release syndrome. (2014) — 2,536 citations
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (2014) — 4,883 citations
- Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia (2012) — 712 citations
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (2011) — 2,431 citations
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma (2010) — 1,648 citations
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome (2009) — 175 citations